Early access
Sign in
Taking people in SwedenPhase 2

Tests stopping BCMA-CD3 antibody treatment in multiple myeloma patients

Studies how long remission lasts after stopping BCMA-CD3 antibody therapy in myeloma.

Key facts

Who runs it
Vaestra Goetalandsregionen
Where
Boras, Falun, Goteborg, Halmstad, Helsingborg, Huddinge, Jonkoping, Linkoping, Lund, Orebro, Trollhattan, Umea, Uppsala, and Varberg, SwedenSee the 14 sites
Registry title
Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment
Status
Recruiting
Phase
Phase 2
People taking part
200 people, planned
Started
22 May 2026
Expected to end
31 Mar 2031
Type of study
Interventional
Record updated
16 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with multiple myeloma who are on BCMA-CD3 bispecific antibody treatment and have a complete response, to see how long remission lasts after stopping it.

Age
18 years or older
Sex
All sexes can join
Disease stage
Multiple myeloma diagnosed by IMWG criteria. Biochemical complete response on treatment, with no measurable M-spike and normal or unmeasurable free light chains. Disease was measurable before treatment started (M-spike >5g/L or involved FLC >100mg/L).
Earlier treatment
Must be on ongoing BCMA-CD3 bispecific antibody therapy. Data on earlier myeloma treatments and baseline data from diagnosis must be available.

Main reasons for not taking part

  • Cannot follow the disease monitoring set out in the protocol
  • Severe other disease with life expectancy under 6 months
  • Cannot give informed consent
  • Multiple myeloma of IgD or IgE type

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • The subject has given their written consent to participate in the trial
  • Multiple myeloma diagnosis according to IMWG criteria
  • On-going BCMA-CD3 bispecific antibody therapy
  • Biochemical complete response (CR), with unmeasurable M-spike and normal or unmeasurable free light chains on local analysis on ongoing BCMA-CD3 bispecific antibody therapy
  • Measurable disease before BCMA-CD3 bispecific antibody treatment initiation by local analysis (defined as M-spike >5g/L or involved FLC >100mg/L)
  • Available baseline data from MM diagnosis
  • Available data on earlier MM treatments
  • 18 years or older

Who cannot take part

  • Severe concomitant disease with life expectancy of < 6 month
  • Subjects who are unable to adhere to the monitoring of the disease according to protocol
  • Subjects without ability to give informed consent
  • Multiple myeloma of IgD or IgE type

Where in Sweden

  • Soedra Aelvsborg Hospital Vaestra GoetalandsregionenBoras, SwedenTaking people
  • Region DalarnaFalun, SwedenTaking people
  • Sahlgrenska University Hospital-Vaestra GoetalandsregionenGoteborg, SwedenTaking people
  • Region HallandHalmstad, SwedenTaking people
  • Region Skane Helsingborg HospitalHelsingborg, SwedenTaking people
  • Karolinska University HospitalHuddinge, SwedenTaking people
  • Region Joenkoepings LaenJonkoping, SwedenTaking people
  • Region OestergoetlandLinkoping, SwedenTaking people
  • Region Skane Skanes UniversitetssjukhusLund, SwedenTaking people
  • Region Oerebro LaenOrebro, SwedenTaking people
  • NU Hospital Group-Vaestra GoetalandsregionenTrollhattan, SwedenTaking people
  • Region VaesterbottenUmea, SwedenTaking people
  • Uppsala University HospitalUppsala, SwedenTaking people
  • Region HallandVarberg, SwedenTaking people

About the trial

What the trial wants to find out

The primary objective of this trial is to assess the duration of remission and therapy free time after stopping BCMA-CD3 bispecific antibody therapy in patients with major M-spike response.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A multicenter prospective trial estimating the persistence of remission after stopping BCMA-CD3 bispecific antibody in multiple myeloma patients with major M-spike response by use MaldiTOF-based high sensitivity monitoring
Plain-language title
Tests stopping BCMA-CD3 antibody treatment in multiple myeloma patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
16 February 2026